Novocure Ltd - Asset Resilience Ratio
Novocure Ltd (NVCR) has an Asset Resilience Ratio of 43.72% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2013–2025)
This chart shows how Novocure Ltd's Asset Resilience Ratio has changed over time. Check Novocure Ltd (NVCR) strategic investment index to assess the company's strategic physical and investment asset allocation.
Liquid Assets Composition Over Time
This chart breaks down Novocure Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Novocure Ltd stock valuation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $344.48 Million | 43.72% |
| Total Liquid Assets | $344.48 Million | 43.72% |
Asset Resilience Insights
- Very High Liquidity: Novocure Ltd maintains exceptional liquid asset reserves at 43.72% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Novocure Ltd Industry Peers by Asset Resilience Ratio
Compare Novocure Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Bio-Rad Laboratories Inc
NYSE:BIO |
Medical Devices | 10.80% |
|
Double Medical Technology Inc
SHE:002901 |
Medical Devices | 12.59% |
|
Tellgen Corp
SHE:300642 |
Medical Devices | 9.96% |
|
Affluent Medical SAS
PA:AFME |
Medical Devices | 0.03% |
|
Cochlear Ltd
AU:COH |
Medical Devices | 9.76% |
|
Anteris Technologies Global Corp
AU:AVR |
Medical Devices | 33.27% |
|
Imricor Medical Systems Inc
AU:IMR |
Medical Devices | 46.50% |
|
Polynovo Ltd
AU:PNV |
Medical Devices | 0.04% |
Annual Asset Resilience Ratio for Novocure Ltd (2013–2025)
The table below shows the annual Asset Resilience Ratio data for Novocure Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 44.03% | $354.13 Million | $804.33 Million | -20.13pp |
| 2024-12-31 | 64.16% | $796.11 Million | $1.24 Billion | +5.72pp |
| 2023-12-31 | 58.44% | $669.79 Million | $1.15 Billion | -13.23pp |
| 2022-12-31 | 71.67% | $854.10 Million | $1.19 Billion | +7.71pp |
| 2021-12-31 | 63.97% | $728.90 Million | $1.14 Billion | +6.18pp |
| 2020-12-31 | 57.79% | $607.90 Million | $1.05 Billion | +26.76pp |
| 2019-12-31 | 31.03% | $148.77 Million | $479.45 Million | +0.05pp |
| 2018-12-31 | 30.98% | $105.26 Million | $339.79 Million | -8.50pp |
| 2017-12-31 | 39.47% | $104.72 Million | $265.30 Million | -3.02pp |
| 2016-12-31 | 42.49% | $119.85 Million | $282.08 Million | -6.32pp |
| 2015-12-31 | 48.81% | $150.00 Million | $307.34 Million | +10.63pp |
| 2014-12-31 | 38.17% | $45.00 Million | $117.88 Million | +37.55pp |
| 2013-12-31 | 0.62% | $1.18 Million | $188.91 Million | -- |
About Novocure Ltd
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, France, Japan, Greater China, and internationally. Its TTFields devices include Optune Gio, Optune Lua, and Optune Pax. The company also has ongoing clinical trials investigating TT… Read more